Le Lézard58 分钟
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment ...
Nektar Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric patients 12 years ...
Nektar receives FDA Fast Track Designation for rezpegaldesleukin
Therapeutics announced that the U.S. FDA has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and ...